NRAS (22%) and HRAS (9%) isoforms are less frequently mutated with melanomas accounting for half of NRAS mutant patients, while head and neck cancer and bladder cancer together account for half of HRAS mutant patients. The gene discussed is NRAS; the disease is urinary bladder cancer.